ClinicalTrials.gg
CompletedNCT07454148Updated Nov 12, 2026

CART-BP Prospective Study for Hypertension Control

An interventional study of CART BP pro and Usual care (office BP-based management) in Hypertension, sponsored by Korea University Anam Hospital. Completed at 1 site in South Korea. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by Korea University Anam Hospital · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 11 months after the study started (first participant enrolled Mar 2025, registered Mar 2026).
Updated Nov 12, 2026Now CompletedResults publication added+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
286
Allocation
Non-randomized
Ages
19 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 353 studies in Hypertension with a site in Korea, Republic of — 30 open to participants now, 41 under way, 11 of them phase 3. Hypertension · Korea, Republic of.

Enrollment
60th of 304
286 · median 110
Started
2025
with 12 others
No phase
30 of 353
6 open now
Registered
337th of 353
by date

Among the 353 studies in Hypertension with a site in Korea, Republic of, this one is the 60th largest by enrollment of the 304 interventional ones that give a count, is one of 13 that started in 2025, is one of 30 with no phase, and was the 337th registered.

Hypertension

6,128 studies on the registry are indexed under Hypertension; 907 are open to participants now.

Browse Hypertension studies →

Open to participants now

30 of the 353 studies in Hypertension with a site in Korea, Republic of are open now. Recruiting first, the newest first:

25 more — sign in →

All 30 open studies →

A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →

Who these studies take

Of the 552 Hypertension studies recruiting now, 260 (47%) set no upper age limit and 198 (36%) stop at 75 or younger; 40 take children under 18; 136 take healthy volunteers.

This study: 19 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 353 studies in Hypertension with a site in Korea, Republic of, or all of them as a file.
02

Study summary

This prospective, open-label, non-randomized study evaluates the effectiveness and safety of a CART BP pro(a brand name of cuffless ambulatory blood pressure monitoring device)-guided blood pressure management strategy in Korean patients with uncontrolled hypertension. Participants are allocated to either a CART BP pro-guided management group or a usual care group based on clinical decision and participant preference. The primary efficacy endpoint is 24-hour mean ambulatory systolic blood pressure at 24 weeks; safety outcomes including treatment-emergent adverse events (TEAEs) are also assessed.

Read the detailed description

Hypertension remains suboptimally controlled despite combination pharmacotherapy, and office blood pressure measurements may not adequately reflect true ambulatory blood pressure burden and nocturnal patterns. CART BP pro is a wearable, cuffless photoplethysmography-based continuous blood pressure monitoring device. This study investigates whether a CART BP pro-guided antihypertensive titration strategy improves 24-hour ambulatory blood pressure control compared with usual care in real-world outpatient settings. Participants receive standard antihypertensive medications (e.g., angiotensin receptor blocker [ARB], calcium channel blocker [CCB], thiazide diuretic) per guideline-based care. In the CART BP pro-guided group, medication adjustments are informed by CART BP pro-derived 24-hour blood pressure data. The planned follow-up was 24 weeks. Prospective data collection under this non-randomized study protocol has ended. The optional extension to 48 weeks was not undertaken. A separate randomized controlled trial, CARTBP-HTN-P2-2025 (NCT07465549), is ongoing to evaluate CART BP pro-guided blood pressure management under a randomized design. Any future analyses of routinely collected clinical data would be retrospective and subject to applicable institutional review board and consent requirements.

The total actual enrollment was 286 participants. The initial publication (PMID: 42846709) reported a subcohort of 246 participants (67 in the CART BP arm and 179 in the usual-care arm) using data available as of April 6, 2026. Eight participants were lost to follow-up. Of the remaining 238 participants, 162 had valid follow-up ambulatory blood pressure recordings and were included in the primary analysis (38 in the CART BP arm and 124 in the usual-care arm); 76 did not have a valid recording. These publication-specific populations are distinct from the total enrollment of the study.

The registered primary outcome is 24-hour mean ambulatory systolic blood pressure at 24 weeks. The publication described the outcome assessment as the 6-month visit and reported median recording times of 181 days after the index visit in the CART BP arm and 188 days in the usual-care arm. Both arms were scheduled to undergo CART BP pro recording for the outcome assessment. Because ambulatory blood pressure was not systematically measured at baseline, the published primary endpoint was the follow-up blood pressure level, not within-participant change from baseline.

03

Conditions studied

  • Hypertension

Browse trials for

Keywords

  • Hypertension
  • Ambulatory blood pressure monitoring
  • Cuffless blood pressure monitoring
  • Wearable blood pressure device
  • CART BP Pro
04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age >= 19 years
  2. Office systolic blood pressure(BP) >= 140 mmHg or diastolic BP >= 90 mmHg
  3. Able and willing to provide written and comply with follow-up visits

Exclusion criteria

Exclusion Criteria:

  1. History of intolerance to olmesartan, amlodipine, or hydrochlorothiazide
  2. Suspected secondary hypertension
  3. Atrial fibrillation
  4. Pregnancy or lactation
  5. Other serious medical condition that may interfere with study participation
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
286 participants (actual)

Study arms

  • Experimental
    CART BP pro-guided management

    Participants undergo 24-hour continuous blood pressure monitoring with CART BP pro. Antihypertensive medications are adjusted based on ambulatory blood pressure data.

    Device: CART BP pro

  • Active comparator
    Usual care

    Participants receive antihypertensive medication adjustments based on office blood pressure measurements according to standard clinical practice.

    Other: Usual care (office BP-based management)

Interventions

  • DeviceCART BP pro

    Wearable cuffless continuous blood pressure monitoring device.

  • OtherUsual care (office BP-based management)

    Standard hypertension management based on office blood pressure.

06

What researchers measure

Primary outcomes

  1. 24-hour mean systolic blood pressure

    Between-group difference in 24-hour mean ambulatory systolic blood pressure measured using the CART BP Pro device at 24 weeks.

    Time frame: 24 weeks

Secondary outcomes

  1. Incidence of treatment-emergent adverse events (TEAE)

    Proportion of participants experiencing TEAEs during the 24-week study period.

    Time frame: 24 weeks

  2. 24-hour blood pressure load

    Percentage of valid ambulatory BP readings exceeding prespecified thresholds over 24 hours.

    Time frame: 24 weeks

  3. Office blood pressure change

    Change in office systolic and diastolic blood pressure from baseline to 24 weeks.

    Time frame: 24 weeks

  4. Target blood pressure achievement rate

    Proportion of participants achieving prespecified ambulatory BP targets.

    Time frame: 24 weeks

07

Study locations

1 site
08

References and documents

Publications

  • Cha JJ, Kim MN, Kim SR, Park JH, Joo HJ, Yu CW. Cuffless 24-hour ambulatory blood pressure monitoring-guided antihypertensive titration in real-world clinical practice: a prospective non-randomized study. Clin Hypertens. 2026 Oct 1;32:e42. doi: 10.5646/ch.2026.32.e42. eCollection 2026. PubMed 42846709 ↗

Individual participant data

Plan to share: No — De-identified individual participant data collected in this study are not currently planned to be shared with external researchers. Data sharing may be considered in the future subject to institutional review board approval and institutional data governance policies.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2025 to primary completion in Apr 2026, 12 months.

Of 1,407 non-industry interventional studies with no phase under Hypertension, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 41. This study's 12 months is below that.

Counting every sponsor, half of 1,502 studies reached it within 23 months; a quarter within 10 and three quarters within 42.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 12, 2026: primary completion May 2026 → Apr 2026 and completion May 2026 → Jul 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Mar 2, 2026
First posted
Mar 6, 2026
StartActual
Mar 25, 2025
Primary completionActual
Apr 22, 2026was May 2026
CompletionActual
Jul 13, 2026was May 2026
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Completed
changed Nov 12, 2026
Primary completion
May 4, 2026→Apr 22, 2026 (actual)
Nov 12, 2026
Study completion
May 4, 2026→Jul 13, 2026 (actual)
Nov 12, 2026
Enrollment
288→286
Nov 12, 2026
Publications
Results publication added: Cha JJ, Kim MN, Kim SR, Park JH, Joo HJ, Yu CW. Cuffless 24-hour ambulatory blood pressure monitoring-guided antihypertensive titration in real-world clinical… PubMed 42846709 ↗
Nov 12, 2026
Show all 1 update
  1. Nov 12, 2026
    Active, not recruiting→Completed
    Publications Results publication added: Cha JJ, Kim MN, Kim SR, Park JH, Joo HJ, Yu CW. Cuffless 24-hour ambulatory blood pressure monitoring-guided antihypertensive titration in real-world clinical… PubMed 42846709 ↗
    Primary completion May 4, 2026→Apr 22, 2026 (now actual)
    Study completion May 4, 2026→Jul 13, 2026 (now actual)
    Enrollment 288→286
    + 2 other changes: verification date and description

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07454148
Responsible party
Hyung Joon Joo (Professor, Korea University Anam Hospital) — Principal investigator
First posted
Mar 6, 2026
Start date
Mar 25, 2025
Primary completion
Apr 22, 2026
Completion
Jul 13, 2026
Last update
Nov 12, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion